Systematic review on anti-diabetic properties of chalcones.
The use of anti-diabetic drugs has been increasing worldwide and the evolution of therapeutics has been enormous. Still, the currently available anti-diabetic drugs do not present the desired efficacy and are generally associated with serious adverse side effects. Thus, entirely new interventions, addressing the underlying etiopathogenesis of type 2 diabetes mellitus, are required. Chalcones, secondary metabolites of terrestrial plants and precursors of the flavonoids biosynthesis, have been used for a long time in the traditional medicine due to their wide-range of biological activities, from which the anti-diabetic activity stands out. This review systematizes the information found in literature about the anti-diabetic properties of chalcones, in vitro and in vivo. Chalcones are able to exert these properties by acting in different therapeutic targets: dipeptidyl peptidase 4 (DPP-4); glucose transporter type 4 (GLUT4), sodium glucose cotransporter 2 (SGLT2), α-amylase, α-glucosidase, aldose reductase (ALR), protein tyrosine phosphatase 1B (PTP1B), peroxisome proliferator-activated receptor-gamma (PPARγ) and adenosine monophosphate (AMP)-activated protein kinase (AMPK). Chalcones are, undoubtedly, promising anti-diabetic agents, and some crucial structural features as already been established. From the structure-activity relationships analysis, it can generally be stated that the presence of hydroxyl, prenyl and geranyl groups in their skeleton improves their activity on the evaluated antidiabetic targets.